ALFAOMEGA Master Observational Trial
ConditionColorectal Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIFOM ETS - The AIRC Institute of Molecular Oncology
About this trial
AlfaOmega has been designed to streamline the study of the co-evolutionary landscape between tumor and host cells in a cohort of CRC patients, with the aim of understanding how their outcomes can be significantly improved (e.g. reduction of their chance of recurrence and survival improval). This clinical resource for integrative clinical data and sample collection will allow the molecular story-telling of CRC metastatic spread along time and space and the selection of appropriate patients for experimentally-driven trials.
Eligibility criteria
Qualifiers
TIER1 written Informed consent.
Patients ≥18 years of age.
Previous diagnosis of colorectal cancer, or a strong suspicion of CRC based on clinical and radiological findings.
In patients with previous diagnosis of CRC availability of diagnostic Formalin-Fixed, Paraffin Embedded (FFPE) blocks (surgical resection and/or tumor biopsies), or at least 10 slides (preferably 20). FFPE tissue blocks are always preferred to slides.
Disqualifiers
Any other current malignancy or malignancy diagnosed or relapsed within the past 5 years (other than non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer)
Patient unable to comply with the study protocol owing to psychological, social or geographical reasons.
Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection.
Trial design
Treatments tested in this trial
- Observation
Treatment groups
3,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov